2852 Kelvin Avenue
717 articles about Masimo Corporation
Masimo (NASDAQ: MASI) will release first quarter 2023 financial results for the period ended April 1, 2023, after the market closes on Tuesday, May 9, 2023.
Masimo (NASDAQ: MASI) today announced that the Rad-G ® with Temperature has received FDA 510(k) clearance.
Masimo Opioid Halo™ Granted De Novo for the First and Only FDA-Authorized Opioid Overdose Prevention and Alert System
Masimo (NASDAQ: MASI) today announced that Masimo Opioid Halo™, an opioid overdose prevention and alert system, has been granted a De Novo by the FDA – making it the first and only FDA-cleared monitoring solution for detecting opioid-induced respiratory depression, the leading cause of death from opioid overdose.
Masimo Corporation announced changes to its Board of Directors and governance policies, the result of an ongoing board refreshment and governance review process informed by regular engagement with stockholders.
New Study Finds That Masimo PVi® Reliably Predicted Fluid Responsiveness in Young Children Undergoing Neurosurgery
Masimo announced the findings of a prospective study published in Pediatrics International in which Dr. Ya-Fei Liu and colleagues at Peking University First Hospital in Beijing evaluated the ability of noninvasive, continuous Masimo PVi®, alongside other dynamic parameters, to predict fluid responsiveness in children 1-3 years old who were undergoing major neurosurgery.
Masimo and Temple Health Form Innovation Collaboration with Focus on Hospital Automation and Telehealth Initiatives
Masimo, a leading global provider of medical technology and automation solutions, and Temple Health, Philadelphia’s 979-bed academic health system, announced that they are entering into a strategic innovation collaboration.
New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Adult Neurosurgical Patients
Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the British Journal of Neurosurgery in which Dr. Ankita Dey and colleagues at institutions in Bathinda and Pondicherry, India evaluated the use of noninvasive, continuous Masimo PVi®.
Masimo (NASDAQ: MASI) today announced that its management will participate in the 44th Annual Raymond James Institutional Investors on Tuesday, March 7, 2023 at 11:00 a.m. Eastern Time.
Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 31, 2022.
New Study Evaluates the Utility of Masimo ORi™ in Reducing Hyperoxemia During Laparoscopic Gastrectomy
Masimo announced the findings of a prospective, double-blinded, randomized controlled study published in Medicine in which Dr. Jin Hee Ahn and colleagues at the Sungkyunkwan University School of Medicine in Seoul, Korea, evaluated the ability of Masimo ORi™ to assist clinicians in guiding supplemental oxygenation during elective laparoscopic gastrectomy surgery.
Masimo to Report Fourth Quarter and FY 2022 Financial Results After Market Close on Tuesday, February 28
Masimo (NASDAQ: MASI) will release fourth quarter and FY 2022 financial results for the period ended December 31, 2022, after the market closes on Tuesday, February 28, 2023.
Masimo (NASDAQ: MASI) today announced the limited market release of Visual Clinical Activity Monitoring (VCAM™), a video analysis system that uses artificial intelligence to help facilitate compliance with hospital hand hygiene protocols.
Researchers Harness the Power of Masimo Root®’s Advanced Multimodal Monitoring Capabilities to Study the Impact of Different Ventilatory Strategies on Brain Oxygenation During Thoracoscopic Surgery
Masimo announced the findings of a prospective, single-blinded, randomized controlled study published in the Journal of Anesthesia & Intensive Care Medicine in which Dr. Mona Mohamed Mogahed and colleagues at Tanta University in Tanta, Egypt and The King Fahd General Hospital in Jeddah, Saudi Arabia, sought to evaluate the impact of varying ventilation strategies on the cerebral oxygenation of patients undergoing video-assisted thoracoscopic surgery.
A United States Administrative Law Judge in Washington, D.C. ruled that Apple Inc. violated Section 337 of the Tariff Act of 1930 as amended, by importing and selling within the United States certain Apple Watches with light-based pulse oximetry functionality and components, which infringe one of Masimo’s pulse oximeter patents.
New Study Evaluates the Performance of Masimo SpHb® Noninvasive Spot-Check Hemoglobin in the Emergency Department
Masimo announced the results of a prospective study published in the American Journal of Emergency Medicine in which Dr. Zohair Ahmed Ali Al Aseri and colleagues at King Saud University Medical City and Dar Al Uloom University evaluated the performance of noninvasive spot-check hemoglobin measurement with Masimo SpHb® on emergency department patients.
New Study Finds That Masimo Patient SafetyNet™ Helped Clinicians Reduce CPR Events and Rates, Improve CPR Success Rate, and Reduce Hospital Length of Stay and Mortality
Masimo announced the findings of a before-and-after study published in PLoS ONE in which Dr. Ahmed Balshi and colleagues at King Saud Medical City in Riyadh, Saudi Arabia, evaluated the impact of implementing remote patient monitoring with Masimo Patient SafetyNet™ on the efficacy of hospital rapid response teams.
New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section
Masimo announced the findings of a prospective study published in the Egyptian Journal of Anesthesia in which Dr. Mohamed Ibrahim Beleta and colleagues at Cairo University evaluated the accuracy of noninvasive, continuous hemoglobin monitoring with Masimo SpHb® on patients undergoing elective cesearan section with antepartum hemorrhage.
Masimo Corporation (Nasdaq: MASI) (“Masimo” or the “Company”) will host its Investor Day today.
New Prospective Study Finds That Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring Can Help Provide Effective Blood Management in Patients Undergoing Major Surgery
Masimo announced the findings of a prospective, double-blinded, randomized, controlled trial published in the Journal of the College of Physicians and Surgeons Pakistan.
Peer-Reviewed Study Finds That Masimo SET® Pulse Oximetry Has No Clinically Significant Difference in Accuracy or Bias Between Black and White People
Masimo (NASDAQ: MASI) today announced the publication of a peer-reviewed study regarding Masimo SET® pulse oximetry performance in varying skin pigmentation in the Journal of Clinical Monitoring and Computing.